Shares of Mylan (NASDAQ:MYL) have been assigned an average recommendation of “Buy” from the twenty-three ratings firms that are currently covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $47.23.
Several equities analysts have recently weighed in on the company. Goldman Sachs raised their price target on Mylan from $46.00 to $52.00 and gave the company a “buy” rating in a report on Thursday, January 11th. Citigroup restated a “buy” rating and set a $58.00 price target (up from $48.00) on shares of Mylan in a report on Thursday, January 4th. Leerink Swann assumed coverage on Mylan in a report on Tuesday, January 2nd. They set a “market perform” rating and a $44.00 price target for the company. JPMorgan Chase set a $53.00 price target on Mylan and gave the company a “buy” rating in a report on Friday, February 16th. Finally, Cantor Fitzgerald set a $41.00 price target on Mylan and gave the company a “hold” rating in a report on Wednesday, April 11th.
In other Mylan news, Director Robert J. Coury sold 150,000 shares of the firm’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $40.10, for a total value of $6,015,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Paul Campbell sold 7,030 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $44.01, for a total value of $309,390.30. Following the completion of the transaction, the insider now directly owns 17,054 shares in the company, valued at $750,546.54. The disclosure for this sale can be found here. Insiders have sold 269,287 shares of company stock worth $11,034,960 over the last ninety days. 0.69% of the stock is currently owned by insiders.
MYL traded down $0.09 during trading on Thursday, reaching $40.72. The stock had a trading volume of 3,430,277 shares, compared to its average volume of 3,627,779. The company has a current ratio of 1.13, a quick ratio of 0.73 and a debt-to-equity ratio of 1.06. The company has a market cap of $20,961.92, a price-to-earnings ratio of 8.93, a price-to-earnings-growth ratio of 1.32 and a beta of 1.34. Mylan has a one year low of $29.39 and a one year high of $47.82.
Mylan (NASDAQ:MYL) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $1.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.41 by $0.02. The business had revenue of $3.24 billion during the quarter, compared to the consensus estimate of $3.29 billion. Mylan had a return on equity of 19.14% and a net margin of 5.84%. The firm’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.57 earnings per share. analysts predict that Mylan will post 5.36 EPS for the current year.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.